Acadia Pharmaceuticals (ACAD) EBT (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly EBT of $4.0 million for Q1 2026, down 85.68% year-over-year from $27.8 million in Q1 2025, and down 84.87% quarter-over-quarter from $26.3 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) EBT (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- In Q1 2026, EBT fell 85.68% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $115.1 million (down 56.55% YoY), while the FY2025 annual figure was $138.9 million, down 46.18% from the prior year.
- EBT for Q1 2026 stood at $4.0 million, down from $26.3 million in the prior quarter.
- The five-year high for EBT was $161.1 million in Q4 2024, with the low at -$112.6 million in Q1 2022.
- The 5-year median for EBT is $21.0 million (2024), against an average of $8.0 million.
- The sharpest annual moves came in 2023 and 2024: EBT slumped 97.35% in 2023, then jumped 486.19% in 2024.
- Acadia Pharmaceuticals' EBT stood at -$40.8 million in 2022, then soared by 197.11% to $39.7 million in 2023, then soared by 306.1% to $161.1 million in 2024, then slumped by 83.67% to $26.3 million in 2025, then sank by 84.87% to $4.0 million in 2026.
- Business Quant data shows ACAD's EBT at $4.0 million in Q1 2026, $26.3 million in Q4 2025, and $44.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 46.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.50 Mn |
| Mar 31, 2026 | 3.98 Mn |
| Dec 31, 2025 | 26.30 Mn |
| Sep 30, 2025 | 44.60 Mn |
| Jun 30, 2025 | 40.20 Mn |
| Mar 31, 2025 | 27.80 Mn |
| Dec 31, 2024 | 161.08 Mn |
| Sep 30, 2024 | 38.80 Mn |
| Jun 30, 2024 | 37.18 Mn |
| Mar 31, 2024 | 21.00 Mn |
| Dec 31, 2023 | 39.66 Mn |
| Sep 30, 2023 | -52.10 Mn |
| Jun 30, 2023 | 6.34 Mn |
| Mar 31, 2023 | -44.90 Mn |
| Dec 31, 2022 | -40.84 Mn |
| Sep 30, 2022 | -26.40 Mn |
| Jun 30, 2022 | -33.57 Mn |
| Mar 31, 2022 | -112.57 Mn |
| Dec 31, 2021 | -42.91 Mn |
| Sep 30, 2021 | -14.79 Mn |